Abstract
Selenium (Se), an essential trace element, has also been identified as an anticarcinogenic agent, with supporting evidence from epidemiological studies, clinical intervention trials, preclinical intervention studies (animal cancer models) and cell culture studies. Natural organic and inorganic sources of Se as well as synthetic organoselenium compounds have been shown to be effective; safety and efficacy factors favour the organic forms. Intakes that are several fold that purported to meet nutritional requirements (adult recommend dietary allowance - 55 μg Se/day) are associated with reductions in cancer risk, but are not currently met by most diets, unless Se-rich foods are included. Further clinical studies and development of tools for speciating Se in foods will enable progress to be made in determining desirable Se forms and foods with respect to providing safe and effective ways of reducing cancer risk.
Keywords: Chemoprevention, colorectal cancer, health benefit, selenium, selenium-rich foods, anticarcinogenic agent, synthetic organoselenium compounds, efficacy factors, selenoproteins, Se-rich soil, organoselenium compounds
Current Pharmaceutical Biotechnology
Title: Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention
Volume: 13 Issue: 1
Author(s): Ying Hu, Graeme H. McIntosh and Graeme P. Young
Affiliation:
Keywords: Chemoprevention, colorectal cancer, health benefit, selenium, selenium-rich foods, anticarcinogenic agent, synthetic organoselenium compounds, efficacy factors, selenoproteins, Se-rich soil, organoselenium compounds
Abstract: Selenium (Se), an essential trace element, has also been identified as an anticarcinogenic agent, with supporting evidence from epidemiological studies, clinical intervention trials, preclinical intervention studies (animal cancer models) and cell culture studies. Natural organic and inorganic sources of Se as well as synthetic organoselenium compounds have been shown to be effective; safety and efficacy factors favour the organic forms. Intakes that are several fold that purported to meet nutritional requirements (adult recommend dietary allowance - 55 μg Se/day) are associated with reductions in cancer risk, but are not currently met by most diets, unless Se-rich foods are included. Further clinical studies and development of tools for speciating Se in foods will enable progress to be made in determining desirable Se forms and foods with respect to providing safe and effective ways of reducing cancer risk.
Export Options
About this article
Cite this article as:
Hu Ying, H. McIntosh Graeme and P. Young Graeme, Selenium-Rich Foods: a Promising Approach to Colorectal Cancer Prevention, Current Pharmaceutical Biotechnology 2012; 13 (1) . https://dx.doi.org/10.2174/138920112798868809
DOI https://dx.doi.org/10.2174/138920112798868809 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer
Current Protein & Peptide Science Commonalities and Differences Between Crohns Disease and Ulcerative Colitis: The Genetic Clues to their Interpretation
Inflammation & Allergy - Drug Targets (Discontinued) Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy
Current Drug Targets Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Indoles - Gut Bacteria Metabolites of Tryptophan with Pharmacotherapeutic Potential
Current Drug Metabolism Salient Features, Data and Algorithms for MicroRNA Screening from Plants: A Review on the Gains and Pitfalls of Machine Learning Techniques
Current Bioinformatics The Analysis of the Druggable Families Based on Topological Features in the Protein-Protein Interaction Network
Letters in Drug Design & Discovery Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients
Inflammation & Allergy - Drug Targets (Discontinued) Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Alternative Spliced Variants as Biomarkers of Colorectal Cancer
Current Drug Metabolism Involvement of MAPK Signalling in Human Villous Trophoblast Differentiation
Mini-Reviews in Medicinal Chemistry Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry